You are now leaving Abacavir HSR Support. ViiV Healthcare does not recommend, endorse or accept liability for sites controlled by third parties.
What is an abacavir HSR?
Abacavir is associated with a risk for hypersensitivity reactions (HSR) characterised by fever and/or rash with other symptoms indicating multi-organ involvement.
An abacavir hypersensitivity reaction (HSR) is an idiosyncratic reaction.
The approximate reporting rate of abacavir HSR in clinical trials was:
- 1% in trials that excluded subjects testing positive for the HLA-B*5701 allele (n=1322)1
- 5% in trials where HLA-B*5701 screening was not performed (n=8038)2
Abacavir HSR is clinically well characterised:3
- Most HSR include fever and/or rash
- Other symptoms include respiratory, gastrointestinal and constitutional symptoms such as lethargy and malaise.
- Multiple symptoms are typical in most cases of hypersensitivity
Diagnosis is complicated by:4
- Variable presentation with nonspecific symptoms
- Concomitant use of other antiretroviral medications with overlapping adverse event profiles
- Potential misdiagnosis of hypersensitivity as respiratory disease (pneumonia, bronchitis, pharyngitis), or gastroenteritis
Note: Symptomatology was evaluated from clinical trials where HLA B*5701 screening was not performed
1. Calculated from published data for four Marketing Authorisation Holder clinical trials: Post F et al. JAIDS. 2010; 55(1): 49-57*, Young B et al. AIDS. 2008; 22: 1673-1675*, Wohl DA et al. PLoS One. 2014; 9(5): e96187*, Walmsley SL et al. N Engl J Med. 2013; 369(19): 1807-1818*
3. Hernandez et al. Abstract presented at: 15th International AIDS Conference; July 11-16, 2004; Bangkok, Thailand. Note: Symptomatology was evaluated from clinical trials where HLA B*5701 screening was not performed.
4. Hetherington et al. Clin Ther. 2001; 23: 1603-1614.*
* ViiV Healthcare does not recommend, endorse or accept liability for sites controlled by third parties.